Sign inJoin waitlistJoin the waitlist

David Schrump

Specialist

Credentials: · · · ·

History

General Surgery
University of Chicago Medical Center
University of Michigan
Carey School of Business, Johns
University of Connecticut School of Medicine

Research

Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
New England Journal of Medicine · 2000 · 797 citations
Ionic immune suppression within the tumour microenvironment limits T cell effector function
Nature · 2016 · 565 citations
Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
Journal of the National Cancer Institute · 1999 · 391 citations

Dao Nguyen
52 papers
CH
Chuong Hoang
24 papers
Taylor Ripley
18 papers · 6 as a fellow
Markku Miettinen
16 papers
Arun Rajan
10 papers
Steven Rosenberg
10 papers · 2 as a fellow
Shamus Carr
9 papers
William Figg
9 papers
AT
Anish Thomas
8 papers
Jack Roth
8 papers
Mary Bechis
8 papers · 4 as a resident
Rishindra Reddy
8 papers · 8 as a resident

Grants

Modulating Cancer Stem Cell Signaling in Thoracic Malignancies
National Cancer Institute · ZIA
Contact PI · $17.4M · Division of Basic Sciences - Nci
Epigenetic Mechanisms of Gene Expression in Thoracic Malignancies
National Cancer Institute · ZIA
Contact PI · $15.1M · Division of Basic Sciences - Nci
Surgical Consultative Services in the Thoracic and Oncologic Surgery Branch
National Cancer Institute · ZID
Contact PI · $12.8M · Division of Basic Sciences - Nci
Epigenetic Therapy for Thoracic Malignancies
National Cancer Institute · ZIA
Contact PI · $11.9M · Division of Clinical Sciences - Nci

Clinical trials

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Principal investigator · Suspended · Phase 1, Phase 2
National Cancer Institute (NCI)
2026–2034
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Principal investigator · Suspended · Phase 1, Phase 2
National Cancer Institute (NCI)
2026–2035
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
Principal investigator · Withdrawn · Phase 2
National Cancer Institute (NCI)
2026
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer
Principal investigator · Withdrawn · Phase 1, Phase 2
National Cancer Institute (NCI)
2024